MYH9-related disorders (MYH9-RD) are the leading cause of inherited
thrombocytopenia(IPD). This autosomal-dominant macrothrombocytopenia
syndrome consisted of the May-Hegglin anomaly, Fechtner syndrome,
Sebastian syndrome, and Epstein syndromes. To date, hematopoietic stem
cell transplantation (HSCT) is the only curative therapy for congenital
thrombocytopenias, such as Wiskott-Aldrich syndrome(WAS) and Glanzmann
thrombasthenia (GT). However, no relevant literature reported on the
outcome of MYH9-related disorders. We first described a pediatric
MYH9-RD patient who underwent a successful myeloablative allogeneic HSCT
with umbilical cord blood stem cells resulting in complete resolution.
Now one year passed after HSCT. The patient’s condition remained stable
during the follow-up. This case highlights the implications of curative
therapy of HSCT in MYH9-RD patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.